Astellas, Sanofi, Lundbeck up for innovation award; Lilly launches online molecule board game;

> Astellas' Dificlir, Sanofi's ($SNY) Lemtrada and Lundbeck's Selincro are a few of the contenders up for the 2014 Innovative Drug Award. Report

> IMS Health has announced it intends to acquire certain Cegedim information solutions and Customer Relationship Management businesses for €385 million ($520 million) in cash. Release

> Forest Laboratories' ($FRX) Viibryd performed significantly better than a placebo for treating generalized anxiety disorder, three late-stage studies show. Report

> Alexion ($AXLN) and Cincinnati Children's Hospital Medical Center have announced the establishment of a collaboration and fund for the advancement of research in rare disease. Release

> A University of Tokyo investigation panel found 'serious faults' in a Novartis ($NVS) significant input of company employees in the trial's planning stages. More

And Finally... Eli Lilly's ($LLY) new online board game, "Destination Discovery," helps users experience the challenges of "bringing a new medicine from molecule to medicine cabinet." More

Suggested Articles

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.

Keytruda's U.S. NSCLC sales might start to fall as soon as early 2020, one analyst says, as I-O rivals eat into its share based on recent successes.

A small group of physicians expressed little interest in new MS drugs from Novartis, Merck KGaA and Biogen but favored a repurposed therapy.